TransMedics Group, Inc. TMDX
At closeNov 6, 2026, 6:58 PM EST
After hours · Nov 6, 6:58 PM ET
- YTD
- -27.46%
- 1 year
- -29.40%
- Market cap
- 3.05B
- Revenue (ttm)
- 727.65M
- Profit margin
- 19.85%
- EPS (ttm)
- 3.86
- Shares out
- 34.56M
- P/E ratio
- 22.86
- Forward P/E
- 39.15
- YTD return
- -27.46%
- 1-year return
- -29.40%
- Volume
- 3.95M
- Avg volume
- 811.72K
- Open
- 79.12
- Previous close
- 68.98
- Day's range
- 76.50 – 88.44
- 52-week range
- 62.04 – 150.42
- Analysts
- Buy
- Price target
- 98.73 (+11.9%)
- Earnings date
- Feb 23, 2027
5D +21.97 (+33.15%)
Key statistics
- Enterprise value
- 2.77B
- PEG ratio
- 0.59
- Price / sales
- 4.19
- Price / book
- 5.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 41.10%
- Free cash flow
- 18.24M
- Total cash
- 492.96M
- Total debt
- 866.90M
- Return on equity
- 31.89%
- Short % of float
- 39.37%
- 50-day average
- 79.69
- 200-day average
- 93.05
Analyst view
Consensus: buy
- Target (low)
- 65.00
- Target (mean)
- 98.73
- Target (high)
- 125.00
- Strong buy3
- Buy6
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.49927.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.43 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.2976 | 0.51 | +0.21 | +71.37% |
| Aug 4, 2026 | Jun 30, 2026 | 0.4955 | 0.44 | -0.06 | -11.20% |
| May 5, 2026 | Mar 31, 2026 | 0.62 | 0.30 | -0.32 | -51.61% |
| Feb 24, 2026 | Dec 31, 2025 | 0.41 | 0.57 | +0.16 | +39.02% |
| Oct 29, 2025 | Sep 30, 2025 | 0.37 | 0.66 | +0.29 | +78.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Needham | main | Buy | Buy |
| Nov 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 13, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 8, 2026 | TD Cowen | reit | Buy | Buy |
| Aug 5, 2026 | UBS | main | Neutral | Neutral |
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- transmedics.com
News
Needham Maintains Buy on TransMedics Group, Raises Price Target to $110 
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $120 
12 Health Care Stocks Moving In Friday's Intraday Session 
Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday 
TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates 
TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript 
TransMedics Group Raises FY2026 Sales Guidance from $737.000M-$757.000M to $750.000M-$760.000M vs $743.798M Est 
12 Health Care Stocks Moving In Thursday's After-Market Session - TransMedics Gr Q3 Adj. EPS $0.51 Beats $0.29 Estimate, Sales $203.005M Beat $177.584M Estimate
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Your note
Sign in to keep a note on TMDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CECERE GIOVANNI | Officer | Stock Award(Grant) | Feb 17, 2026 | 19,057 |
| CORCORAN NICHOLAS | Officer | Stock Award(Grant) | Jul 9, 2026 | 41,558 |
| FORSYTH MATTHEW S | General Counsel | Stock Award(Grant) | May 18, 2026 | 15,409 |
| GUNDERSON THOMAS JAMES | Director | Sale | Jun 14, 2026 | 16,642 |
| HASSANEIN WALEED H | Chief Executive Officer | Stock Award(Grant) | Jul 9, 2026 | 666,102 |
| HERNANDEZ GERARDO | Chief Financial Officer | Stock Award(Grant) | Jul 9, 2026 | 31,935 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.19% | 5,596,549 | 493.84M | Jun 29, 2026 |
| FMR, LLC | 14.85% | 5,133,328 | 452.96M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.60% | 1,933,989 | 170.66M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.33% | 1,497,600 | 132.15M | Jun 29, 2026 |
| State Street Corporation | 4.11% | 1,420,421 | 125.34M | Jun 29, 2026 |
| Nomura Asset Management International Inc | 2.63% | 910,495 | 80.34M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.97% | 2,064,603 | 182.18M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,038,890 | 91.67M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.56% | 885,083 | 78.10M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 752,168 | 66.37M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.10% | 726,130 | 64.07M | Aug 30, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 1.79% | 617,377 | 54.48M | Aug 30, 2026 |